Coming through Q120 bruised and expecting much harder punches before the calm, companies ride the COVID-19 storm
Among the many topics covered in the comprehensive Q120 US Joint Fluid Replacement Market Recap* are:
- Complete Market Overview with Company Revenues and Shares
- Single-Injection: Leading the HA Market
- 2-Injection: Fidia's Hymovis Revenue Growth
- 3-Injection: Downward Trend Continues
- 5-Injection: Negative Growth
- Notable Achievement in Q120
Although demand, adoption rate, and awareness continue to fuel growth for the lowest HA treatment options, with single-injection and 2-injection YoY positive growth, this was not enough to pull the entire US Joint Fluid Replacement market into positive territory for Q120. Additionally, not only did the COVID-19 crisis impact total revenue at the tail-end of Q120, some HA players are indicating that suppliers of extended-release corticosteroid, as well as Platelet-Rich Plasma (PRP) injectable products are making a more aggressive competitive push into the HA market...
*The entire article can only be viewed by SmartTRAK subscribers to this module. For more information on how to receive a demo and subscribe, please click the button below.
